Document is current
Any future updates will be listed below
-
Authors
Dolezal, James M. http://orcid.org/0000-0002-6788-7203
Srisuwananukorn, Andrew http://orcid.org/0000-0002-8736-8726
Karpeyev, Dmitry
Ramesh, Siddhi
Kochanny, Sara
Cody, Brittany
Mansfield, Aaron S. http://orcid.org/0000-0002-9483-6903
Rakshit, Sagar
Bansal, Radhika http://orcid.org/0000-0003-0964-098X
Bois, Melanie C.
Bungum, Aaron O.
Schulte, Jefree J. http://orcid.org/0000-0003-3920-0301
Vokes, Everett E.
Garassino, Marina Chiara
Husain, Aliya N.
Pearson, Alexander T. http://orcid.org/0000-0003-2801-7456
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01-CA243075)
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (R56-DE030958)
Cancer Research Foundation
EIF | Stand Up To Cancer
EC | Horizon 2020 Framework Programme (2021-SC1-BHC I3LUNG)
- License Information
-
More Information
Article History
Received: 5 May 2022
Accepted: 7 October 2022
First Online: 2 November 2022
Competing interests
: D.K. is an employee of DV Group, LLC, but holds no competing interests for this work. A.T.P. reports no competing interests for this work, and reports personal fees from Prelude Therapeutics Advisory Board, Elevar Advisory Board, AbbVie consulting, Ayala Advisory Board, and stock options ownership in Privo Therapeutics, all outside of submitted work. E.E.V. is a consultant and provides advisory roles for AstraZeneca, Beigene, BioNTech, Eli Lilly, EMD Serono, Genentech/Roche, GlaxoSmithKline, and Novartis, with no competing interests for this work. All remaining authors report no competing interests.
